Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (July 2023)
11 slides from Cynata Therapeutics's investor presentation, Jul 27, 2023
Slide 1: ASX Announcement: Investor Webinar Presentation
ASX ANNOUNCEMENT 27 July 2023 Investor Webinar Presentation Melbourne, Australia; 27 July 2023: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical- stage biotechnology company specialising in cell therapeutics, is pleased to release the presentation that will be deliver
Slide 2: A Next Generation Stem Cell Therapeutics Company
For personal use only A Next Generation Stem Cell Therapeutics Company Strategic Review Presentation July 2023
Slide 3: Introduction to new CEO
Introduction to new CEO “ It is a great honour and privilege to be appointed as CEO and For personal use only Managing Director of Cynata at such an exciting time in the company's journey of developing its therapeutic stem cell Dr Kilian Kelly platform technology, CymerusTM. CEO & MD • Appointed as
Slide 4: Strategic review of product pipeline completed
Strategic review of product pipeline completed Cynata has an advanced product pipeline targeting attractive market opportunities across a range of indications Target area Trial phase Market opportunity For personal use only Cynata Sponsored Acute Graft vs Host Disease (aGvHD) Phase 2 ready1 US$0.6bn
Slide 5: aGvHD Phase 2 clinical trial
aGvHD | Phase 2 clinical trial Cynata plans to commence recruitment during the current quarter, with results expected H2 CY 2025 For personal use only • Acute Graft vs Host Disease (aGvHD) is a complication that can occur after Key Milestones aGvHD a bone marrow transplant when the donor’s immune ce
Slide 6: DFU Phase 1 clinical trial
DFU | Phase 1 clinical trial High screening failure rate has resulted in slower than expected recruitment, Cynata has undertaken steps to accelerate recruitment rate with enrolment expected to be completed by the end of CY 2023 For personal use only Diabetic Foot • Diabetic Foot Ulcers (DFU) are sor
Slide 7: OA Phase 3 clinical trial
OA | Phase 3 clinical trial1 Recruitment accelerating and expected to be completed by the end of CY 2023, with evaluation results expected to be released in CY 2026 For personal use only • Osteoarthritis (OA) occurs when the cartilage in a joint wears away and Key Milestones Osteoarthritis can cause
Slide 8: Renal Phase 1 clinical trial
Renal | Phase 1 clinical trial Clinical trial start up activities with partner Leiden University Medical Center (LUMC) underway, with outcome from regulatory approval process expected during the current quarter For personal use only • MSCs may reduce or eliminate the requirement for aggressive and t
Slide 9: Investment Highlights
Investment Highlights Cynata is a clinical stage biotech developing its proprietary Cymerus platform technology for the scalable manufacture of mesenchymal stem cell (MSC) therapeutic products to treat serious disorders For personal use only Unique Strong safety Large Multiple Fully funded Manufactu
Slide 10: Important information
Important information Summary information ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, ‘potential’ and other similar This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries expressions. The forward looking statem
Slide 11: Contact Us
For personal use only Contact Us Cynata Therapeutics Limited Contact details: Level 3 100 Cubitt Street kilian.kelly@cynata.com Cremorne Victoria 3121 www.cynata.com Australia
Cynata Therapeutics — Investor Presentation (July 2023) on 6ix